Nearly 2,000 Pink Walkers returned to the Peak for Step Up for Breast Health

HONG KONG, Oct. 16, 2023 /PRNewswire/ — The annual flagship fundraising event, "Pink Walk 2023" organised by the Hong Kong Breast Cancer Foundation (HKBCF), was successfully held on 15 October in the Breast Cancer Awareness Month at the Peak, Hong Kong Island. With close to 2,000 pink walkers participating, the "Pink Walk" has gathered collective strength from the city to support the HKBCF’s work.

Themed "Step Up for Breast Health", "Pink Walk 2023" aims to raise public awareness of the threat of breast cancer in Hong Kong and raise funds to support the HKBCF’s work in breast health education, patient support services, and research and advocacy. The HKBCF calls on everyone to maintain regular exercise habits to safeguard one’s own health.

The recently released Hong Kong Breast Cancer Registry Report No.15 by HKBCF revealed that regular Mammography (MMG) screening for women can help early detection of breast cancer, improve postoperative survival rates, reduce medical costs, and avoid unnecessary treatments. Dr. Eliza Fok, Chairman of HKBCF, said, "Since its establishment 18 years ago, the HKBCF has been raising funds to provide, amongst other services and work, partially or fully sponsored MMG screening and patient support services for women from the low-income families."

Dr. Fok expressed her heartfelt gratitude to all guests, donors, volunteers and pink walkers for their generous support to make this meaningful event possible. The officiating guests who joined Dr. Fok and Dr. Polly Cheung, Founder of HKBCF, at the Kick-off Ceremony included Mrs. Janet Lee Lam Lai-sim, Wife of the Chief Executive of the Hong Kong Special Administrative Region of the People’s Republic of China, who is also the Honorary Patron of HKBCF; The Honourable Mr. Tommy Cheung Yu-yan, GBM, GBS, JP, member of the Legislative Council of Hong Kong (LegCo) and Chairman of the LegCo’s Panel on Health Services (2023); Mr. Henry Fan Hung-ling, SBS, JP, Chairman of the Hospital Authority; Mrs. Rita Fan Hsu Lai-tai, GBM, GBS, CBE, JP, Special Counsellor of Our Hong Kong Foundation and Former member of National People’s Congress (NPC) Standing Committee, who is also the former Honorary President of the HKBCF; Ms. Chan Yuen-han, GBS, JP, Chairperson of the Women’s Commission of LegCo, and HKBCF Ambassadors Ms. Nancy Sit , Miss Bernice Liu, Ms. Mimi Kung and Miss Ashley Lin. Dr. Fok reiterated that she believed the HKBCF’s work can help alleviate the pressure on the public healthcare system and provide appropriate support to those in need. "We are committed to continue serving the needy in our community", Dr Fok added.

During the Kick-off Ceremony, Mr. Henry Fan, SBS, JP, Chairman of the Hospital Authority, said, "Thank you to HKBCF’s ongoing advocacy for better breast cancer care in Hong Kong. It coheres a strong patient support network in the community. I believe that under the leadership of Dr. Eliza Fok and Dr. Polly Cheung, the HKBCF will continue to provide quality services to the people in Hong Kong, from breast cancer education, prevention to patient support. The Hospital Authority is looking forward to strengthening the cooperation with the HKBCF."

Actress Ms. Mimi Kung and her daughter, Miss Ashley Lin, the mother-daughter duo, appealed for public support to the HKBCF and urged everyone to pay attention to breast health as well as general physical and mental health. HKBCF ambassadors, Ms. Nancy Sit and Miss Bernice Liu whilst encouraged everyone to have regular health screening, they also emphasised the importance of prioritising physical well-being amidst busy work schedules.

With growing popularity of adopting a healthy lifestyle in our community, HKBCF continues to encourage women to cultivate a habit of regular breast examinations. It also calls on all pink walkers to spread breast health messages to those around them. The HKBCF has been advocating for population-wide breast screening with the goal of helping more women to be free from the threat of breast cancer which will help build a better and healthier Hong Kong.

Pink Walkers Shined in Splashes of Pink

Similar to past years, the Best Dressed Pink Awards provided contestants a platform to try their best to outshine other Pink Walkers. The Best Dressed Pink Awards were presented to the individual, team, pet, and kid who attended the charity walk with the most eye-catching outfit. The HKBCF also presented Awards to Top Individual, Small Team, Organisation/Large Team Fundraisers, as well as Highest Participation team so as to express our appreciation for their dedicated support.

List of Awardees:

Individual Top Fundraiser Award – Champion

Dr. Eliza Fok

Individual Top Fundraiser Award – 1st Runner-up

Mrs. April Chan

Individual Top Fundraiser Award – 2nd Runner-up

Mrs. Margaret Chan-Thorp

Top Fundraiser Award (Small Team) – Champion

HKSH Medical Group

Top Fundraiser Award (Small Team) – 1st Runner-up

Dr. Polly Cheung’s Clinic

Top Fundraiser Award (Small Team) – 2nd Runner-up

The Korean Women’s Association of Hong Kong

Top Fundraiser Awards (Organisation/Large Team) – Champion

Let’s Pink

Top Fundraiser Awards (Organisation/Large Team) – 1st Runner-up

Ralph Lauren Asia Pacific Limited

Top Fundraiser Awards (Organisation/Large Team) – 2nd Runner-up

Fly Pink Hong Kong

Highest Participation Award

Ralph Lauren Asia Pacific Limited

Best Dressed PINK Award – Individual

Mr. Parvesh Shamdasani

Best Dressed PINK Award – Team

Fly Pink Hong Kong

Best Dressed PINK Award – Kid

Michale Lau

Best Dressed PINK Award – Pet

Janice Hou’s dog

Thanks to the following individual/sponsors, supporting organisations, and media partner, "Pink Walk 2023" was held successfully:

Platinum Sponsor:

ICON HK Medical Services Limited

Sapphire Sponsors:

American Express Richemont Asia Pacific Ltd – Cartier Dr. Betty Chan Ng Teng Fong Charitable Foundation Shih Wing Ching Foundation Ltd. YOU Group Hong Kong Ms. Nina Kan

Gold Sponsors:

CLP Power Hong Kong Ltd. Diagnostix Medical Centre Ltd. GYU Ltd Hong Kong Women’s Imaging Ms. Alice Liu Pfizer Corporation Hong Kong Ltd Pierre Fabre Varian Medical Systems Vita Green Health Products Co., Ltd. Mr. Larry Yung

Silver Sponsors:

Hengan Pharmacare Co., Ltd. Bonluxe (Asia) Ltd. Chun Wo Construction Holdings Company Ltd. Daiichi Sankyo Hong Kong Limited AstraZeneca Hong Kong Limited DAKS London Deckers Brands HKSH Medical Group Hologic Asia Pacific Limited Jacobson Medical (Hong Kong) Limited Kennedys Dr. George Lam & Mrs. Kathy Lam Eli Lilly Asia, Inc. Luen Thai Holdings Ltd. MUSEE PLATINUM TOKYO Roche Hong Kong Ltd. Ms. Barbara Shiu Dr. Patrick P.C. Tong Y.L Yang Foundation Esquel Group

Supporting Organisations:

Andrex HK ANESSA Artistry Hengan Pharmacare Co., Ltd. BioEm Air Sanitizing Technology Co. Ltd. Bonluxe (Asia) Ltd. Chevalier International Holdings Ltd. Embry (H.K.) Ltd. Evolcare Hang Lung Properties Heliservices (HK) Ltd. Hong Kong Disneyland  HK Electric Hoya Kerry Lifestyle Ltd. Illume House Imasa HK Ltd. DCH Auriga(HK) Ltd –JAMIESON The Korean Women’s Association of H.K. Lee Kum Kee Group Mary Kay (Hong Kong) Ltd. Ocean Park Corporation Pura Pharm International (HK) Ltd.

Ralph Lauren Pink Pony Shangri-la International Hotel Management Ltd. Shun Hing Electronic Trading Co., Ltd. Sino Group SYL Holding Ltd. Target Storage Ltd. The Green Earth The Peninsula Boutique Tiberius Productions Limited TITIKA Active Couture Vita Green Health Products Co., Ltd. VITAS LIMITED VOILA Watsons Water YOU Group Hong Kong 212 studio

Media Partner

Citybus (Bravo Transport Services Limited) CVISION MCP Meditorial MostTown MTR Corporation Limited Sassy Hong Kong Sassy Mama Square Mile Times Square Limited (Hong Kong)

Official Radio Station:

Metro Broadcast

Download event photos: https://bit.ly/46u5itz

About Hong Kong Breast Cancer Foundation

The Hong Kong Breast Cancer Foundation was set up on 8 March 2005, as a non-profit charitable organisation dedicated to mitigating the threat of breast cancer to the local community through education, patient support and research and advocacy. Its mission is to promote breast health awareness, support breast cancer patients on their road to recovery, and advocate breast health education and cancer care in Hong Kong.

Source : Hong Kong Breast Cancer Foundation – "Pink Walk 2023" Charity Walk Concluded Successfully

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

TAIPEI, Oct. 16, 2023 /PRNewswire/ — LITEON Technology (2301.tw) continues to set industry milestones with its latest portfolio addition: a Level 3 Electric Vehicle (EV) DC fast charger. Launched by Power Innovations International (Pii) – a subsidiary of LITEON – these EV chargers easily integrate with existing electrical infrastructure due to their multi-voltage input, which enables users to quickly install the product while avoiding additional infrastructure and installation costs. These can be integrated in any input voltage configuration found in US power distribution infrastructure with no derating to the base power purchased.

The EV charger portfolio comes with modular and stackable power capabilities – and no derating feature among any of the different input configurations. Pii recently installed 30 and 60 kilowatt versions onsite with a US partner, showcasing its adaptability to use available existing infrastructure from 240 Vac up to 480 Vac in the same product with no derating. With LITEON’s power electronic expertise and industry-leading technology, users can expect a rapid and seamless charging experience.

Pii Provides Cutting-edge DC EV Charging Solutions from 30kW to 180kW

Pii is a US-based company that specializes in providing clean, efficient power solutions. It has long been an industry leader in power management solutions – in particular, uninterruptible power supplies and power distribution equipment since its founding in 1997 – and now includes EV charging solutions. LITEON acquired Pii in 2013, combining LITEON’s global reach and manufacturing capabilities with Pii’s expertise in critical power applications. This charger represents the first time that a Pii product has incorporated LITEON’s power conversion technology in a design.

Pii’s EV DC fast charging systems, ranging from 30kW up to 180kW, offer high-speed charging solutions that are suitable for private or public use, including public EV infrastructure, EV fleets, dealerships, C-Store, and similar commercial applications, as well as mobile fast charging.

Pii’s experience in delivering reliable power solutions ensures that users receive high-quality charging equipment. With the desire for green energy systems, Pii is committed to providing sustainable solutions that align with their values for the latest smart energy ecosystems. For more information about Pii’s solutions, please visit https://powerinnovations.com/.

Source : LITEON Power Innovations Showcases Installation of Level 3 DC Fast Charger with Partner

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

VICTORIA, Seychelles, Oct. 16, 2023 /PRNewswire/ — Bitget, a leading cryptocurrency derivatives and copy trading platform, proudly announces the victorious teams of its Under 30 Virtual Hackathon, a dynamic initiative within the Blockchain4Youth CSR program. The competition, which unfolded from August 12 to September 24, 2023, witnessed outstanding innovation in the realms of AI and blockchain.

Bitget’s Blockchain4Youth U30 Hackathon Unveils Winners: Nurturing Young AI and Blockchain Innovators

With a robust collaboration between Bitget and industry leaders, including Bitget Wallet,  Foresight Ventures and HackerEarth, the U30 Hackathon offered a total prize pool of $40,000, attracting over 1,000 teams of young talents who showcased remarkable creativity and technological acumen. The judging panel for this event consisted of Bitget’s internal blockchain experts, ensuring that the winning submissions demonstrated not only innovation but also the viability and impact required for real-world applications.

The competition involved three captivating themes:

Trustless Infrastructure for AI: Contestants demonstrated their innovative skills by creating a trustless infrastructure for AI, ensuring secure and private AI applications using zero-knowledge proofs (zkp) and zk-SNARKs. Their solutions also empowered developers with zero-knowledge proofs and zero-knowledge proofs empowered AI DApps and zkml (zero-knowledge machine learning), enabling secure and private machine learning applications using blockchain technology. AIGC and Web3 Gaming: The gaming industry is one of the fastest-growing sectors worldwide, but it faces challenges in scalability, security, and transparency. Participants developed solutions that leveraged AIGC and blockchain technology to revolutionize Web 3 gaming, enhancing immersion and trust for players. AI Marketplace: With AI and ML gaining popularity, ensuring secure and private AI applications is crucial. Participants in this challenge created an AI marketplace that ensured the secure and transparent exchange of AI algorithms and data with the help of blockchain technology.

Winners emerged in distinct categories below, each receiving $10,000 in recognition of their exceptional work:

Impact to Blockchain Community: Lilium, for their innovative carbon offset program that employs blockchain to verify carbon credits. Most Creative Solution: Grease Pencil, creators of an AI-infused storyboard builder. Most Viable Solution: Explore the World, developers of an NFT-based game where businesses offer coupons on NFTs for collecting and using. Best Design: Derma 360, for their AI-powered skin problem diagnosing pen.

Gracy Chen, Managing Director of Bitget, expressed her delight at the results, saying, "This Hackathon exemplifies the creativity and potential of our future leaders and is deeply aligned with Bitget’s overarching Blockchain4Youth initiative, which seeks to inspire blockchain and cryptocurrency adoption among young individuals. The ideas and innovations presented here will undoubtedly shape the future of the crypto and blockchain industries."

About Bitget
Established in 2018, Bitget is the world’s leading cryptocurrency exchange and web3 company. Serving over 20 million users in 100+ countries and regions, the Bitget exchange is committed to helping users trade smarter with its pioneering copy trading feature and other trading solutions. Formerly known as BitKeep, Bitget Wallet is a world-class multi-chain crypto wallet that offers an array of comprehensive Web3 solutions and features including wallet functionality, swap, NFT Marketplace, DApp browser, and more. Bitget inspires individuals to embrace crypto through collaborations with credible partners, including legendary Argentinian footballer Lionel Messi and official eSports events organizer PGL.

For more information, visit: Website | Twitter | Telegram | LinkedIn | Discord | Bitget Wallet

https://platform.twitter.com/widgets.js

Source : Bitget's Blockchain4Youth U30 Hackathon Unveils Winners: Nurturing Young AI and Blockchain Innovators

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

– Nine abstracts, featuring the effectiveness of Lunit’s AI-powered TIL/WSI analyzer and biomarker platform, accepted by the ESMO 2023 Congress

SEOUL, South Korea, Oct. 16, 2023 /PRNewswire/ — Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced the presentation of 9 studies at the upcoming European Society for Medical Oncology (ESMO) 2023 Congress, to be held in Madrid, Spain, from October 20-24.

Lunit AI-powered TIL analyzer, Lunit SCOPE IO

During this year’s congress, Lunit plans to highlight the predictive value and analytical power of its Lunit SCOPE suite, offering valuable insights for understanding the tumor microenvironment, predicting treatment responses, and accurately assessing HER2 scores, in various types of cancer such as biliary tract cancer, head and neck squamous cell carcinoma, and non-small cell lung cancer.

A collaborative study indicated that AI-based immune phenotyping can predict therapy outcomes in advanced biliary tract cancer (BTC) patients who are planning to be treated with anti-PD-1 therapy. A total of 337 H&E-stained whole slide images (WSI) were acquired for assessment. In the study, the research team defined the immune phenotype of the WSI samples via Lunit SCOPE IO, Lunit’s AI TIL (tumor-infiltrating lymphocytes) analyzer. Among the three immune phenotypes (inflamed; immune-excluded; immune-desert), the inflamed group showed enhanced overall survival (12.5 vs. 5.1 months), progression-free survival (5.0 vs. 2.0 months), and objective response rates (27.5% vs. 7.7%), compared to the non-inflamed group.

In another study, it was found that TIL density in tumor microenvironment is highly correlated with favorable treatment response to immune checkpoint inhibitor (ICI) in head and neck squamous cell carcinoma (HNSCC). Assessed by Lunit SCOPE IO, patients with high-TIL showed a higher objective response rate (21.6% vs 5.7%) and more favorable median progression-free survival (3.2 vs 1.6 months).

Lunit also plans to present the results of three trials during this year’s congress. A joint trial with the Mayo Clinic unveils that epithelial TIL demonstrated the highest ability to distinguish between MMR-D (Mismatch repair deficiency) and MMR-P (Mismatch repair proficiency) tumors in colon cancer. The post-hoc exploratory analysis results of three clinical trials utilizing Lunit SCOPE IO in Italy and France are also set to be showcased.

In another study, HER2 (human epidermal growth factor receptor-2) scoring in biliary tract cancer was evaluated using Lunit SCOPE HER2. The analysis showed a substantial concordance of 75.3% between AI and human pathologists’ assessments.

Another study aimed to predict multiple druggable mutations in non-small cell lung cancer (NSCLC) based on AI analysis of H&E images. More than 3,000 NSCLC samples were used as training data to develop an AI-powered predictive model. In validation in an independent dataset, the model showed robust performance in predicting six types of mutations (EGFR-mt, KRAS-mt, ALK-tr, ROS1-tr, RET-tr, MET-ex). Notably, for MET exon skipping mutations, the model achieved a high positive predictive value (PPV), showing that test-positive patients were three times more likely to have true-MET-ex positive mutations compared to the overall patient population. Moreover, specificity and PPV for identifying patients without mutations (All-WT) were 99.2% and 95.2% respectively, which means with AI assistance unnecessary tests can be avoided. Following the results, it is expected that the newly developed AI genotype predictor, available for multiple genotypes in non-small cell lung cancer, holds immense potential for widespread adoption by clinicians and pharmaceutical industry leaders globally.

"We are thrilled to be at this year’s ESMO with nine groundbreaking study results that prove the effectiveness of the Lunit SCOPE AI WSI analyzer and biomarker platform," said Brandon Suh, CEO of Lunit. "The study results emphasize the substantial progress made with Lunit SCOPE IO, building compelling evidence of the critical role of immune phenotyping in understanding cancer biology and optimizing treatment strategies. We remain committed to advancing this transformative technology through further research and development."

For inquiries or to schedule a meeting with the Lunit team, please contact [email protected].

Lunit’s Abstracts at ESMO 2023

No.

Poster
No. #

Title

Type

1

118P

Artificial intelligence (AI)-powered spatial analysis of tumor-
infiltrating lymphocytes (TILs) as a predictive biomarker for anti-PD-
1 in advanced biliary tract cancer (BTC)

Poster

2

874P

Artificial intelligence (AI)-powered spatial tumor-infiltrating
lymphocyte (TIL) analysis in recurrent/metastatic (r/m) head and
neck squamous cell carcinoma (HNSCC) patients treated with
immune checkpoint inhibitor (ICI) treatment

Poster

3

569P

Clinical Trial of artificial intelligence for detection of mismatch
repair deficiency in colon carcinomas (alliance)

Poster

4

366P

Artificial Intelligence(AI)-powered Assessment of Complete and
Intense Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
Tumor Cell Proportion in Breast Cancer: Predicting Fluorescence In
Situ Hybridization (FISH) Positivity and Response to HER2-Targeted
Therapy

Poster

5

1930P

Phase II clinical trial of avelumab in combination with gemcitabine
in advanced leiomyosarcoma as a second-line treatment (KCSG
UN18-06)

Poster

6

123P

Artificial intelligence (AI)-powered analysis of human epidermal
growth factor receptor-2 (HER2) and tumor-infiltrating lymphocytes
(TILs) in advanced biliary tract cancer (BTC)

Poster

7

571P

Artificial intelligence-powered analysis of tumor lymphocytes
infiltration: a translational analysis of AtezoTRIBE clinical trial

Poster

8

2330P

Pre-test prediction of multiple druggable mutations based on H&E
image artificial intelligence (AI) analysis may enable more efficient
clinical workflow for treatment decisions in non-small cell lung
cancer (NSCLC)

Poster

9

–

Late Breaking Abstract

–

About Lunit

Lunit is a deep learning-based medical AI company on a mission to conquer cancer. Our focus is on developing AI solutions for precision diagnostics and therapeutics, ensuring the right diagnosis, and treatment, at the right cost for each patient. Lunit is devoted to developing advanced medical image analytics and AI-based biomarkers via cutting-edge technology.

Founded in 2013, Lunit has been acknowledged around the world for its advanced, state-of-the-art technology and its application in medical images. As a medical AI company grounded on clinical evidence, the company’s findings are presented in major peer-reviewed journals, such as the Journal of Clinical Oncology and JAMA Network Open, and global conferences, including ASCO and AACR.

After receiving FDA clearance and the CE Mark, our flagship Lunit INSIGHT suite is clinically used in approximately 2,000+ hospitals and medical institutions across 40+ countries. Lunit is headquartered in Seoul, South Korea, with offices and representatives worldwide. For more information, please visit lunit.io

About Lunit SCOPE

Lunit SCOPE is a suite of AI-powered software that analyzes tissue slide images for digital pathology and AI biomarker development, aiming to optimize workflow and facilitate more accurate and predictive clinical data for clinicians and researchers.

Lunit SCOPE platform offers multiple AI-powered tissue analysis products and assays that can streamline digital pathology workflow and diagnostics and enhance the drug development process.

Lunit SCOPE IO analyzes the tumor microenvironment (TME) based on H&E analysis and provides AI-based predictive clinical outcome information. In addition, AI-driven Immunohistochemistry (IHC) slide analysis services are offered, through products such as Lunit SCOPE PD-L1, Lunit SCOPE HER2, Lunit SCOPE ER/PR, and others.

Source : New Study Demonstrates Lunit SCOPE IO's Effectiveness to Predict Biliary Tract Cancer Therapy Outcomes – Findings to be Presented at the ESMO 2023

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

Deploying First Units in a Breakthrough Field Trial Program

FORT LAUDERDALE, Fla., Oct. 16, 2023 /PRNewswire/ — Global energy infrastructure leader, Prolec, has teamed up with Ubicquia, an innovator in intelligent utility infrastructure, to build the industry’s first fully integrated smart transformer. The new transformers deliver real-time monitoring and grid analytics. Units have begun shipping to North American utilities for field trials.

Industry’s first integrated intelligence transformer coming off-the-line from Prolec and Ubicquia.

The companies collaborated to integrate Ubicquia’s UbiGrid™ distribution transformer monitoring (DTM+) platform into Prolec’s single-phase pad mount transformers across a wide range of sizes. The integration, testing and certification is performed in Prolec’s Monterrey, Mexico facility, one of the largest distribution transformer manufacturing facilities in North America.

The UbiGrid DTM+ platform is the first distribution transformer monitoring platform providing real-time electrical and physical transformer health data along with advanced grid analytics deployed at scale. Ubicquia has delivered more than 30,000 units to monitor single-phase and three phase transformers to major utilities across the US and Latin America. Prolec customers can now receive transformers pre-equipped with the intelligence needed for proactive transformer, grid, and supply chain intelligence. By integrating the UbiGrid DTM+ platform into its transformers, Prolec eliminates the need for utilities to retrofit units in the field and reduces the total cost for a smart transformer.

The initial use cases for the intelligent transformer include:

–  Predicting transformer outages to improve reliability;
–  Detecting and diagnosing issues with failed assets to optimize field resources and improve storm response;
–  Improving capacity planning, which has become more complex with the significant growth in electric vehicles, supply chain constraints, and distributed energy generation; and
–  Providing additional resilience for industrial and critical loads.

Commercial availability of the intelligent transformer is planned for 2024.

"This is a significant step forward in the evolution of transformers," said Ricardo Suarez, CEO of Prolec. "We are thrilled to partner with Ubicquia and shape the future of smart energy."

"Our partnership with Prolec is a vision coming to life. By delivering smart transformers, from the factory at scale, we are enabling a new age of grid analytics, and we are just getting started," said Ian Aaron, CEO of Ubicquia.

About Prolec
Internationally recognized for quality manufacturing and reliable performance for over 50 years, Prolec is an electric industry leader in the Americas with four business units—Prolec GE, Prolec Celeco, Prolec Energy Solutions and Prolec Labs—and six manufacturing facilities strategically located in Mexico, the United States, and Brazil. Our broad transformer services offering in the U.S. as well as our wide variety of transformer components complement Prolec’s full line of transformer solutions for the generation, transmission, and distribution of electrical energy for utilities, co-ops, municipalities, renewable project developers and original equipment manufacturers. As a leading supplier of critical infrastructure, Prolec embraces its commitment to providing an exceptional customer experience, superior quality products, comprehensive solutions and on-time deliveries while actively developing innovative, responsible, and sustainable solutions to solve the industry’s challenges.

To learn more, visit www.prolec.energy or follow us on LinkedIn.

About Ubicquia 
Ubicquia’s intelligent infrastructure platforms install in minutes and make the world smarter, safer, and more connected. Our smart grid products attach to existing distribution transformers in minutes, providing predictive analytics that make the grid more resilient. Our smart city solutions simply plug into the photocell sockets of 360 million compatible streetlights to reduce energy consumptions, enhance public safety, and lower operations and maintenance costs. Our communication platforms use existing streetlights to expand public broadband and help mobile operators accelerate their 5G and FWA deployments. Ubicquia® products are deployed by more than 700 customers that include the largest cities, utilities, and mobile operators across North America. To learn more visit www.ubicquia.com or follow us on Twitter and LinkedIn.

https://platform.twitter.com/widgets.js

Source : Prolec and Ubicquia Unveil Industry's First Transformer with Integrated Intelligence

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

SHANGHAI, Oct. 16, 2023 /PRNewswire/ — MultiMetaVerse Holdings Limited ("MMV" or the "Company"), an animation and entertainment company for young consumers in China, announced today that it has received a letter of approval from the Listing Qualifications Department of the Nasdaq Stock Market ("Nasdaq") on October 13, 2023 for its application to transfer the listing of its class A ordinary shares and warrants. The Company previously submitted an application to Nasdaq to transfer the listing of its class A ordinary shares and warrants from the Nasdaq Global Market to the Nasdaq Capital Market. The transfer will be effective at the opening of business on October 17, 2023. The class A ordinary shares and warrants of the Company will continue to trade under the symbol "MMV" and "MMVWW", respectively.

The Nasdaq Capital Market is a continuous trading market that operates in the same manner as the Nasdaq Global Market. All companies listed on the Nasdaq Capital Market must meet certain financial requirements and adhere to Nasdaq’s corporate governance standards. The Company believes it is in compliance with all applicable criteria for continued listing on The Nasdaq Capital Market.

About MultiMetaVerse Holdings Limited

MultiMetaVerse Holdings Limited (NASDAQ: MMV) is an animation and entertainment company dedicated to providing a high-quality, immersive entertainment experience through original, user-generated, and professional user-generated content. MMV’s signature Aotu World brand has attracted a broad following among younger audiences in China. By leveraging the company’s established user base, MMV has built a diverse product portfolio, including animated content, comic books, short videos, collectables, stationery, consumer products, and mobile games across the Aotu World brand.

For more information, please visit https://www.multi-metaverse.com/. 

For investor and media inquiries, please contact:

MultiMetaVerse Holdings Limited
Investor Relations
E-mail: [email protected] 

Safe Harbor Statement

This press release contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Without limiting the generality of the foregoing, the forward-looking statements in this press release include descriptions of the Company’s future commercial operations. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, such as the Company’s inability to implement its business plans, identify and realize additional opportunities, or meet or exceed its financial projections and changes in the regulatory or competitive environment in which the Company operates. You should carefully consider the foregoing factors and the other risks and uncertainties described in the Company’s Annual Report on Form 20-F and other documents filed or to be filed by the Company with the SEC from time to time, which could cause actual events and results to differ materially from those contained in the forward-looking statements. All information provided herein is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.

Source : MultiMetaVerse Announces Listing Transfer to Nasdaq Capital Market

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network